Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

63.30 -0.36 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,921,087
Open 63.20
Bid (Size) 63.28 (1)
Ask (Size) 63.60 (5)
Prev. Close 63.66
Today's Range 63.09 - 63.53
52wk Range 61.73 - 76.56
Shares Outstanding N/A
Dividend Yield 1.47%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry
Via Benzinga
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront... 
Via Talk Markets

Performance

YTD
-8.70%
-8.70%
1 Month
+0.57%
+0.57%
3 Month
-8.45%
-8.45%
6 Month
-11.38%
-11.38%
1 Year
-4.40%
-4.40%

More News

Read More
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant
Via The Motley Fool
3 No-Brainer Stocks to Buy With $1,000 Right Now
Via The Motley Fool
5 Growth Stocks to Buy for 2024
Via InvestorPlace
Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
From AstraZeneca
Via Business Wire
3 stocks that crushed earnings estimates and still tanked
Via MarketBeat
Exposures COVID-19
US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges
Via Benzinga
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
Via The Motley Fool
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
Via Benzinga
Exposures Product Safety
TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
From AstraZeneca
Via Business Wire
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
Via Benzinga
Exposures Product Safety
AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip.
Via InvestorPlace
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
Via Talk Markets
The 7 Next Trillion Dollar Companies to Invest in to Become a Millionaire
Via InvestorPlace
AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Auto Trader & AstraZeneca Help FTSE Reverse Early Losses
Via Talk Markets
AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs
Via Investor's Business Daily
AstraZeneca Joins Anti-Obesity Race Dominated By Eli Lilly And Novo Nordisk, Reports Mixed Q3 Earnings
Via Benzinga
Wall Street To Snap Longest Winning Streak Since 2021 Today? Earnings, Bond Yields In Focus Ahead Of Powell's Speech
Via Benzinga
Earnings Review: AstraZeneca Increases Profit Outlook, Reports 17% EPS Growth
Via Talk Markets
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
From AstraZeneca
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.